Secondary Plasma Cell Leukemia Life Expectancy

Given that actual treatment of spcl is unsatisfactory novel therapeutic approaches are needed in order to improve outcome and quality of life in these patients.

Secondary plasma cell leukemia life expectancy.

Plasma cell leukemia pcl is an aggressive form of multiple myeloma characterized by high levels of abnormal plasma cells circulating in the peripheral circulating blood. Plasma cell leukemia is more commonly seen in african americans than caucasians. Normal plasma cells in the bone marrow produce antibodies that fight infection. Traditionally pcl has been diagnosed based on kyle s criteria which requires circulating plasma cells to account for at least 20 of peripheral blood leukocytes and or an absolute circulating plasma cell count of 2 0 10 9 l with evidence of monoclonal gammopathy jimenez zepeda and dominguez 2006 some investigators consider this number to be arbitrary and have.

Secondary plasma cell leukemia occurs in 1 to 4 patients out of 100 patients who are with myeloma and it is becoming more common as the life span of myeloma patients is increasing. Plasma cell leukemia pcl is a plasma cell dyscrasia i e. Plasma cell leukemia is a rare and typically very aggressive form of blood cancer. I was diagnosed with primary plasma cell leukemia in 2012.

Pcl manifests when the cancerous plasma cells are seen in the bloodstream not just in the bone marrow. Secondary plasma cell leukemia represents an aggressive proliferative disorder associated with a poor prognosis and a shorter survival compared to mm itself. I had never had myeloma before it was my original diagnosis. Men are at a slightly increased risk for developing plasma cell leukemia than women.